$135 Million is the total value of Opus Point Partners Management, LLC's 67 reported holdings in Q1 2017. The portfolio turnover from Q4 2016 to Q1 2017 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| XBI | SPDR SERIES TRUSTs&p biotech | $9,014,000 | +17.1% | 130,000 | 0.0% | 6.69% | +9.1% | |
| IBB | ISHARES TRnasdq biotec etf | $7,332,000 | +10.5% | 25,000 | 0.0% | 5.44% | +3.0% | |
| MRK | MERCK & CO INC | $5,318,000 | +7.9% | 83,700 | 0.0% | 3.95% | +0.6% | |
| BMY | BRISTOL MYERS SQUIBB CO | $4,894,000 | -7.0% | 90,000 | 0.0% | 3.63% | -13.3% | |
| BIB | PROSHARES TR | $4,102,000 | +20.9% | 85,000 | 0.0% | 3.04% | +12.7% | |
| PFE | PFIZER INC | $3,842,000 | +5.3% | 112,300 | 0.0% | 2.85% | -1.9% | |
| AZN | ASTRAZENECA PLCsponsored adr | $3,737,000 | +14.0% | 120,000 | 0.0% | 2.77% | +6.2% | |
| MTD | METTLER TOLEDO INTERNATIONAL | $3,442,000 | +14.4% | 7,188 | 0.0% | 2.56% | +6.6% | |
| GSK | GLAXOSMITHKLINE PLCsponsored adr | $2,530,000 | +9.5% | 60,000 | 0.0% | 1.88% | +2.0% | |
| BMY | BRISTOL MYERS SQUIBB COcall | $2,447,000 | -7.0% | 45,000 | 0.0% | 1.82% | -13.3% | |
| PCRX | PACIRA PHARMACEUTICALS INC | $2,280,000 | +41.2% | 50,000 | 0.0% | 1.69% | +31.5% | |
| CLVS | CLOVIS ONCOLOGY INC | $1,910,000 | +43.3% | 30,000 | 0.0% | 1.42% | +33.5% | |
| PRTK | PARATEK PHARMACEUTICALS INC | $1,540,000 | +25.0% | 80,000 | 0.0% | 1.14% | +16.5% | |
| TSRO | TESARO INC | $1,539,000 | +14.4% | 10,000 | 0.0% | 1.14% | +6.5% | |
| MDCO | MEDICINES CO | $1,369,000 | +44.1% | 28,000 | 0.0% | 1.02% | +34.2% | |
| LLY | LILLY ELI & COcall | $1,262,000 | +14.4% | 15,000 | 0.0% | 0.94% | +6.6% | |
| ADMS | ADAMAS PHARMACEUTICALS INC | $1,050,000 | +3.6% | 60,000 | 0.0% | 0.78% | -3.6% | |
| PTLA | PORTOLA PHARMACEUTICALS INC | $980,000 | +74.7% | 25,000 | 0.0% | 0.73% | +62.6% | |
| SNR | NEW SR INVT GROUP INC | $854,000 | +4.3% | 83,700 | 0.0% | 0.63% | -2.8% | |
| CFRX | CONTRAFECT CORP | $540,000 | +2.9% | 300,000 | 0.0% | 0.40% | -4.1% | |
| AVXS | AVEXIS INC | $380,000 | +59.0% | 5,000 | 0.0% | 0.28% | +48.4% | |
| MCRB | SERES THERAPEUTICS INC | $158,000 | +13.7% | 14,000 | 0.0% | 0.12% | +5.4% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-05-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| METTLER-TOLEDO INTL CMN | 20 | Q3 2019 | 4.7% |
| ALNYLAM PHARMACEUTICALS, INC. CMN | 20 | Q3 2019 | 5.0% |
| VERTEX PHARMACEUTICALS INC CMN | 20 | Q3 2019 | 4.0% |
| ILLUMINA, INC. CMN | 20 | Q3 2019 | 4.4% |
| SEATTLE GENETICS, INC. CMN | 20 | Q3 2019 | 4.0% |
| ALEXION PHARMACEUTICALS INC CMN | 20 | Q3 2019 | 4.3% |
| INCYTE CORPORATION CMN | 20 | Q3 2019 | 4.4% |
| NEKTAR THERAPEUTICS CMN | 20 | Q3 2019 | 4.9% |
| REGENERON PHARMACEUTICALS | 20 | Q3 2019 | 3.8% |
| CELGENE CORPORATION CMN | 20 | Q3 2019 | 3.8% |
View Opus Point Partners Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2019-11-14 |
| 13F-HR | 2019-08-14 |
| 13F-HR | 2019-05-15 |
| 13F-HR | 2019-02-14 |
| 13F-HR | 2018-11-14 |
| 13F-HR | 2018-08-14 |
| 13F-HR | 2018-05-15 |
| 13F-HR | 2018-02-14 |
| 13F-HR/A | 2017-11-17 |
| 13F-HR | 2017-11-14 |
View Opus Point Partners Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.